What is the 13F Pro Quality Score for ALLR?

13F Pro ranks Allarity Therapeutics, Inc. (ALLR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALLR's current score at https://13fpro.ai/research/ALLR (free sign-up required for the full ranking).

Where does 13F Pro source ALLR data?

All Allarity Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Allarity Therapeutics, Inc. files with the SEC under CIK 1860657. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALLR in?

Allarity Therapeutics, Inc. (ALLR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALLR research updated on 13F Pro?

ALLR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Allarity Therapeutics, Inc.(ALLR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1860657 ALLR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ALLR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Allarity Therapeutics, Inc. (ALLR), a Healthcare sector company. ALLR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Allarity Therapeutics, Inc. reports quarterly revenue of $25.0K, net income of $-2.8M, free cash flow of $-4.6M. Top institutional holders of ALLR by reported 13-F value include RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ALLR trades on the Nasdaq exchange and files with the SEC under CIK 1860657. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALLR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Allarity Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$25.0K

Net Income

Q1 2026

$-2.8M

Free Cash Flow

Q1 2026

$-4.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2024

FY21 —FY22 —FY23 —FY24 $0.00

Net Income

-106.0% YoY

$-24.5MFY 2024

FY21 $-26.6MFY22 $-16.1MFY23 $-11.9MFY24 $-24.5M

Operating Income

-59.0% YoY

$-27.2MFY 2024

FY21 $-26.6MFY22 $-34.5MFY23 $-17.1MFY24 $-27.2M

EPS (Diluted)

—FY 2024

FY21 $-4.19FY22 $-3093.42FY23 $-10.26FY24 —

Total Assets

+90.9% YoY

$22.6MFY 2024

FY21 $49.6MFY22 $14.5MFY23 $11.9MFY24 $22.6M

Total Debt

—FY 2024

FY21 —FY22 $2.6MFY23 $2.9MFY24 —

Op. Cash Flow

-36.1% YoY

$-17.4MFY 2024

FY21 $-14.9MFY22 $-16.8MFY23 $-12.7MFY24 $-17.4M

Metric	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$0.00	—	—	—
Net Income	$-24.5M -106.0%	$-11.9M +25.9%	$-16.1M +39.7%	$-26.6M
Operating Income	$-27.2M -59.0%	$-17.1M +50.3%	$-34.5M -29.8%	$-26.6M
EPS (Diluted)	—	$-10.26 +99.7%	$-3093.42 -73728.6%	$-4.19
Total Assets	$22.6M +90.9%	$11.9M -18.4%	$14.5M -70.7%	$49.6M
Total Debt	—	$2.9M +11.1%	$2.6M	—
Operating Cash Flow	$-17.4M -36.1%	$-12.7M +24.2%	$-16.8M -13.0%	$-14.9M

AI Insight: ALLR Financial Trends

Pre-revenue biotech burning $3M quarterly with equity base eroded to $7M; debt spiked to $20M in Q1 2026.

• Operating losses stabilized at $3M/quarter from Q1 2025 onwards, down from $12M in Q3 2024.

• Operating cash burn narrowed to $3–5M/quarter since Q1 2025, versus $7M in Q2 2024.

• Equity base collapsed from $20M (Q2 2024) to $7M (Q1 2026); debt rose to $20M in latest quarter.

⚠ Company remains pre-revenue ($0M reported Q1 2026) with no visible commercialization inflection.

⚠ Leverage inverted sharply: debt now 2.9× equity (Q1 2026). Runway at current burn ~1.75 years.

AI Insight: ALLR Ratio Trends

Allarity remains deeply unprofitable with deteriorating returns; ROE plunged to -159% in Q1 2026, though ROA improved sequentially from Q4 2025's -73.9%.

• ROE collapsed from -32.9% in Q2 2024 to -159.0% in Q1 2026, signaling sustained net losses eroding shareholder value.

• ROA worsened from -21.1% in Q2 2024 to -31.5% in Q1 2026, indicating asset base cannot generate positive returns.

• Leverage (D/E) stable at 2.90 in TTM and Q1 2026, unchanged from Q4 2024 despite persistent operating losses.

⚠ ROA improved to -31.5% in Q1 2026 from -73.9% in Q4 2025 — check if reflects genuine operational progress or seasonal timing.

⚠ High debt/equity (2.90) compounds burn from negative returns; refinancing risk if losses persist and liquidity tightens.

Get alerted when ALLR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Allarity Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALLR

RENAISSANCE TECHNOLOGIES LLC
$248.6K228,084 sh
GEODE CAPITAL MANAGEMENT, LLC
$207.5K190,393 sh
VANGUARD CAPITAL MANAGEMENT LLC
$187.3K171,795 sh
STATE STREET CORP
$150.0K137,600 sh
VANGUARD FIDUCIARY TRUST CO
$81.7K74,913 sh
NORTHERN TRUST CORP
$52.4K48,103 sh
XTX Topco Ltd
$31.6K28,967 sh
TWO SIGMA INVESTMENTS, LP
$30.0K27,492 sh
UBS Group AG
$25.2K23,158 sh
TWO SIGMA SECURITIES, LLC
$13.4K12,334 sh

Fund	Value	Shares
RENAISSANCE TECHNOLOGIES LLC	$248.6K	228,084
GEODE CAPITAL MANAGEMENT, LLC	$207.5K	190,393
VANGUARD CAPITAL MANAGEMENT LLC	$187.3K	171,795
STATE STREET CORP	$150.0K	137,600
VANGUARD FIDUCIARY TRUST CO	$81.7K	74,913
NORTHERN TRUST CORP	$52.4K	48,103
XTX Topco Ltd	$31.6K	28,967
TWO SIGMA INVESTMENTS, LP	$30.0K	27,492
UBS Group AG	$25.2K	23,158
TWO SIGMA SECURITIES, LLC	$13.4K	12,334

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALLR on your watchlist

Track score changes the day Allarity Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALLR a good stock to buy?

13F Pro's AI-powered analysis of Allarity Therapeutics, Inc. (ALLR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALLR are available on the ALLR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALLR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALLR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Allarity Therapeutics, Inc.'s investment landscape.